Plexitome™, a groundbreaking new device for anterior stromal puncture (ASP), is now available through a strategic partnership between Plexitome Medical and VEO Ophthalmics, an industry leader of innovative ophthalmic technologies. Designed to provide unmatched precision and consistency, Plexitome™ is poised to become a game-changing option in the treatment of Recurrent Corneal Erosion (RCE) and other epithelial basement membrane dystrophies (EBMD).

Unlike traditional tools, Plexitome™ features a 6.2 mm diameter disc array with approximately 675 precisely engineered micro-spikes, delivering controlled and uniform puncture depth through Bowman's layer of the cornea—without creating optically evident anterior stromal scarring. With up to 3,375 individual epithelial attachment points created over five imprints, the device enhances corneal healing and reduces long-term recurrence rates.

"Plexitome™ represents a significant step forward in the management of corneal disorders, particularly in the optical axis. The device was engineered to improve outcomes while eliminating the unpredictability and limitations of manual ASP," said Dr. Edward Chaum, Founder and Chief Medical Officer at Plexitome Medical. "VEO Ophthalmics has a history of bringing innovative products to market, and we are excited to partner with them for our commercialisation strategy."

"Plexitome Medical has developed a truly innovative approach to treating RCE and large corneal abrasions," Said Ron Gilliland, CEO of VEO Ophthalmics. "Plexitome™ is sure to reinvent how cornea specialists utilise anterior stromal puncture. We are pleased to work together with Plexitome Medical to bring this new technology to cornea specialists and their patients."